Joy Gibson, MD, PhD

Dr. Gibson’s laboratory seeks to optimize treatment regimens for challenging infections. Our primary focus is management of drug-resistant bacterial infections in cystic fibrosis, particularly non-tuberculous mycobacteria. We utilize a hollow fiber infection model to optimize current therapeutics and test novel treatment approaches in vitro.

• Albert Einstein College of Medicine, Bronx, NY — MD, PhD — 05/2013
• University of Colorado School of Medicine, Aurora, CO — 06/2016 — Pediatrics Residency
• Children's Hospital Los Angeles, Los Angeles, CA — 07/2023 — Pediatric Infectious Diseases Fellowship

• Antibiotic optimization
• Drug-resistant bacteria
• Cystic Fibrosis
• Pharmacokinetics-pharmacodynamics

• Transcriptome profiles of macrophages upon infection by morphotypic smooth and rough variants of Mycobacterium abscessus. Microbes Infect. 2024 Jul-Aug; 26(5-6):105367.. View in PubMed
• Growth medium and nitric oxide alter Mycobacterium abscessus morphotype and virulence. Microbiol Res. 2021 Dec; 253:126887.. View in PubMed

• Neely, Michael